Purpose Living-donor lobar lung transplantation (LDLLT) has been successfully performed in Japan. In LDLLT, the recipient usually receives one lower lobe from each of two donors; however, finding two ABO-matched donors is often difficult. Solid organ transplants from donors with minor ABO-mismatches can be complicated by hemolysis. We investigated the incidence of de novo anti-ABO antibody production and hemolysis in patients receiving LDLLT across minor ABO-mismatches. Methods We evaluated 23 patients who underwent LDLLT between June 2008 and December 2011, including 11 patients who underwent minor ABO-mismatched transplantation. We measured the anti-A/B antibody serum titers, hemoglobin concentrations and indirect bilirubin levels. Results None of the patients showed any clinical signs of hemolytic anemia (mean follow-up period; 16 months). Two of the 11 patients (18 %) receiving minor ABOmismatched LDLLTs showed a small amount of de novo anti-B antibodies for a transient period. These patients showed gradual progression of anemia, and weak de novo anti-A/B antibodies were detected with column agglutination technology. The patients received only 2 U of washed type O red blood cells; thereafter, the hemolytic anemia did not develop further in either case. Conclusion LDLLT across minor ABO-mismatches results in the transient appearance of weak de novo anti-A/B antibodies with a low incidence; thus, this procedure can be a safe treatment.
Introduction
The shortage of organ donors for patients requiring lung transplantation is more critical than that for any other solid organ. To address this issue, living-donor lobar lung transplantation (LDLLT) has been performed in Japan since 1998 [1, 2] . After the Japanese organ transplantation law was revised, the frequency of lung transplantations using brain-dead donors increased; however, the necessity of performing LDLLT, particularly in urgent cases, remains unchanged. Performing LDLLT using two ABOmatched donors according to the current protocol for LDLLT is often difficult. Solid organ transplants from donors with minor ABO-mismatches can be complicated by hemolysis [3, 4] , and performing LDLLT using minor ABO-mismatched donors is unavoidable. We reviewed our single-institutional experience of LDLLT and investigated the incidence of de novo anti-ABO antibody production and hemolysis in patients receiving LDLLT across minor ABO-mismatches.
Patients and methods
We performed LDLLTs at Kyoto University in 25 patients between June 2008 and December 2011. Two patients were excluded because one patient died of multiple organ failure unrelated to ABO-mismatches in the early phase of the post-transplant period and one patient received a major ABO-mismatched transplant. The case of the patient who underwent the major ABO-mismatched transplantation has been reported previously; the patient exhibited O? erythrocytes without anti-A/B antibodies after undergoing bone marrow transplantation and received lobar lung transplants from donors with B? and AB? blood groups [5] . Therefore, we assessed 11 minor ABO-mismatched and 12 ABOidentical recipients. We routinely measured the serum titers of anti-A and anti-B antibodies, determined the rhesus phenotypes and screened for irregular antibodies using column agglutination technology (CAT) in all patients on post-transplant days (PTDs) 5, 8 and 14. When hemolytic anemia related to anti-A or anti-B antibodies was suspected, the serum titers of these antibodies were measured. Moreover, if blood transfusions were necessary, crossmatching was performed using standard tube methods and/ or CAT. We used the hemoglobin concentrations and indirect bilirubin levels to determine the presence of hemolysis. Each patient was given an adequate explanation of the nature of the proposed investigation or treatment, and informed consent was obtained from all patients.
Results
Among the 11 patients who underwent minor ABO-mismatched transplantation, three pediatric patients underwent transplantation of a single lobe. The remaining eight adult patients underwent transplantation of both lung lobes: three patients received transplants from both donors with minor ABO-mismatches (Table 1) . One patient died of pneumonia 3 months after transplantation, while the others survived; none of the patients showed any clinical signs of hemolytic anemia (follow-up period: 3.3-44.7 months; mean: 16 months). Two of the 11 patients (18 %) who underwent minor ABO-mismatched transplantation showed small amounts of de novo anti-A/B antibodies on PTD 27 and 39. The remaining 12 patients who underwent ABO-identical transplantation during the same period did not show the presence of de novo anti-A/B antibodies.
Case 1
A 28-year-old female (blood group B?) with idiopathic interstitial pneumonia underwent LDLLT using a right lower lobe from her mother (58 years old; blood group O?) and a left lower lobe from her aunt (56 years old; blood group O?). She received 34 U of type B red blood cells during the intraoperative period. The patient's postoperative course was relatively uneventful. The immunosuppressive therapy included three drugs, namely, cyclosporine, azathioprine and prednisone. The first episode of acute rejection on PTD 5 required intravenous administration of high-dose methylprednisolone and alteration of azathioprine to mycophenolate mofetil; the second episode of acute rejection on PTD 10 required the same steroid therapy as that administered on PTD 5, and cyclosporine was changed to tacrolimus. On PTD 12, the patient received 2 U of type B red blood cells due to progressive decreases in the hemoglobin concentrations. The anemia gradually progressed again from PTD 21, and weak anti-B antibodies were detected with CAT and confirmed using standard tube methods on PTD 27. The levels of indirect bilirubin increased during this period. The patient received 2 U of red cell concentrates from PTD 7 until the appearance of anti-B antibodies. Since then, she has received only 2 U of washed type O red blood cells, and no further progression of hemolytic anemia has been observed (Fig. 1) .
Case 2
A 44-year-old male (blood group O?) had acute myeloid leukemia and received an allogeneic peripheral blood stem In planning for a blood transfusion to treat progressive anemia on PTD 39, no anti-B antibodies were detected using CAT or standard tube methods. Cross-matching with type B red blood cells was performed using CAT because that day was a holiday, and the results revealed a positive cross-match. The levels of indirect bilirubin were high during this period. The patient received 8 U of red cell concentrates from PTD 7 until a positive cross-match was achieved. Since then, he has received only 2 U of washed type O red blood cells, and no further progression of hemolytic anemia has been observed (Fig. 2) .
Discussion
Production of ABO antibodies by the graft against the recipient's red blood cells has previously been reported after transplantation of minor ABO-mismatched solid organs [3] . Passenger lymphocyte syndrome (PLS) is the clinical phenomenon of autoimmune hemolysis resulting from adoptive transfer of viable lymphocytes from the donor during solid organ or hematopoietic stem cell transplant. The frequency of PLS appears to be related to the volume of transplanted lymphoid tissue [6, 7] . Typically, antibodies appear 7-10 days after transplantation and are present for approximately 1 month. Several authors have found that the immunoglobulins primarily belong to the IgG class [8] . Ramsey et al. [3] reported that the incidence of antibody detection and hemolysis is low in kidney transplant patients, intermediate in liver transplant patients and high in heart-lung transplant patients. Magrin et al. [9] reported the first instance of hemolytic anemia across a minor ABO-mismatch in a lung-only transplant recipient. Since then, several reports have been published [4, [10] [11] [12] . Taaning et al. [10] reported the case of patient with severe hemolysis caused by graft-derived anti-B production following bilateral lung (O group to B group) transplantation. Salerno et al. [4] reported the cases of four single and three bilateral lung transplant patients with minor ABO-mismatched transplants. Two of the four patients who received single lung transplants developed donor ABO antibodyderived hemolysis. Sano et al. reported the cases of 13 patients with minor ABO-mismatched LDLLT, of whom five developed anti-A or B antibodies in the serum and only one exhibited hemolytic anemia [11, 12] . In our study, we evaluated 11 patients who underwent minor ABO-mismatched LDLLT, of whom two developed anti-B antibodies in the serum, and both showed hemolytic anemia. An LDLLT recipient requires two ABO-identical or minor ABO-mismatched donors; therefore, the tendency for minor ABO-mismatches is high in LDLLT. In our study, three of the eight adult patients who underwent LDLLT had both grafts across minor ABO-mismatches (Table 1) . However, the incidence of hemolytic anemia in our study was low, and the patients recovered immediately. Approximately 20 years ago, CAT was introduced to automate immunohematology testing [13] . At our institution, we routinely use CAT first for the following reasons. The sensitivity of CAT is superior to that of standard tube methods. In addition, the IgG class of anti-A/B antibodies is clinically more important than the IgM class; therefore, CAT, which detects antibodies belonging to the IgG class more easily than standard tube methods, is more effective. Historically, performing testing before the administration of a blood transfusion to determine the ABO group and D type has been performed by visually scoring antibody-mediated RBC agglutination in test tubes after centrifugation [14] . In Case 2 of this study, no alloantibodies were detected using either CAT or standard tube testing; however, a few alloantibodies were detected with CAT during cross-matching.
In the event of a hemolytic crisis due to donor ABO antibodies, washed type O red blood cells are administered at our institution. Ogo et al. [15] and Bakr et al. [16] also reported the use of washed type O red blood cells to treat hemolytic anemia in living-donor lobar lung and kidney transplantation patients. In contrast, Hunt et al. [8] reported the successful use of group O red blood cells. Petz concluded that, although packed red blood cells contain anti-A and/or anti-B that are reactive to the patient's red blood cells, hemolysis caused by transfusion of plasma in red blood cells is rare; therefore, using washed red blood cells is generally unnecessary [17] . To minimize the possible adverse effects of transfusions, we used washed type O red blood cells. This option might lead to a smooth recovery from hemolytic anemia. In conclusion, LDLLT across minor ABO-mismatches results in the transient appearance of weak de novo anti-A/B antibodies with a low incidence. Despite the small number of cases, LDLLT can be a safe treatment.
